Drug Profile
NI 0701
Alternative Names: NI-0701; NI-0701/α-RANTESLatest Information Update: 08 Nov 2019
Price :
$50
*
At a glance
- Originator NovImmune SA
- Developer Light Chain Bioscience
- Class Monoclonal antibodies
- Mechanism of Action Chemokine CCL 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in United Kingdom (IV, Infusion)
- 19 Feb 2014 Phase I development is ongoing in Europe
- 06 Dec 2010 Phase-I clinical trials in Autoimmune disorders in United Kingdom (IV)